Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Teva Pharmaceutical Industries Limited American Depositary Shares
(NY:
TEVA
)
17.05
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jul 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries Limited American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Teva Releases Q2 2025 Aide Memoire
June 26, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
June 26, 2025
Via
Benzinga
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
June 26, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END
Via
FinancialNewsMedia
How Do Investors Really Feel About Teva Pharmaceutical Indus?
June 05, 2025
Via
Benzinga
Where Teva Pharmaceutical Indus Stands With Analysts
May 28, 2025
Via
Benzinga
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
June 25, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
June 25, 2025
Via
The Motley Fool
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
June 16, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
June 18, 2025
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters
June 16, 2025
Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
June 18, 2025
From
FN Media Group LLC
Via
GlobeNewswire
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
June 06, 2025
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.
Via
Benzinga
9 Health Care Stocks Whale Activity In Today's Session
June 04, 2025
Via
Benzinga
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
June 03, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
June 03, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
May 30, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with
May 30, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030
May 29, 2025
Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base.
Via
Benzinga
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
May 29, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead
May 28, 2025
Duquesne Family Office's chief dumped his entire stake in one of Wall Street's premier stock-split stocks and has continued to load up on a super-cheap drug company for a third straight quarter.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Government
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
May 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
May 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Why Is Teva Stock Trading Higher On Tuesday?
May 27, 2025
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.
Via
Benzinga
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
May 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
May 22, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
May 20, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
May 20, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
May 19, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
May 19, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
May 15, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.